Nav: Home

First in-vivo trial of subharmonic contrast-enhanced imaging for detection of PCa

May 06, 2019

Leesburg, VA, May 6, 2019--A new technique for imaging of microbubble ultrasound contrast agents may be useful in detection of prostate cancer (PCa) not found by multiparametric magnetic resonance imaging (MRI), according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, HI.

The first in vivo application of contrast-enhanced SHI in the prostate, the pilot study was conducted to evaluate contrast-enhanced subharmonic imaging (SHI) of the prostate for detection of PCa.

Building on the authors' previous work demonstrating the effectiveness of contrast enhanced harmonic imaging (HI) for detection of prostate cancer, 55 patients referred for prostate biopsy were imaged using conventional grayscale, color, and power Doppler, conventional contrast HI, SHI -- a new technique for imaging of microbubble ultrasound contrast agents with up to a 10-fold increase in contrast-to-background signal ratio relative to conventional HI -- and flash replenishment in combination with SHI (MIP-SHI).

The results demonstrated contrast-enhanced SHI enhancement in all patients. Detection of PCa using contrast-enhanced SHI included 9 of 31 patients with a prior negative MRI or negative MRI-guided biopsy, suggesting SHI may be useful in detection of PCa not found by multiparametric MRI.

"Diagnosis of clinically significant prostate cancer with non-invasive means is a real clinical challenge," said author of the study Ethan Halpern, MD. " Although multi-parametric MRI is currently used for this purpose, ultrasound has numerous advantages. Ultrasound systems are portable. Ultrasound studies are far less expensive and more widely available as compared with MRI. Contrast enhanced ultrasound studies can be performed at the same sitting as the ultrasound-guided biopsy, while mp-MRI requires two visits, one for the diagnostic MR study and a second for the fusion biopsy. There is no need for a fusion imaging system (additional hardware/software) when using contrast enhanced ultrasound. No additional effort is required to properly register the contrast-enhanced ultrasound diagnostic study with the targeting system for biopsy. Combining contrast enhanced ultrasound with subharmonic imaging has the potential to provide a new, non-invasive method for diagnosis and characterization of prostate cancer."
-end-
With educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2019 Annual Meeting, May 5-10, at the Hawaii Convention Center in Honolulu, Hawaii. For more information, visit: http://www.arrs.org/am19.

American Roentgen Ray Society

Related Prostate Cancer Articles:

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.
Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.
First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.
Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.
CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.
Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.
Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.
ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer.
Patient prostate tissue used to create unique model of prostate cancer biology
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Moffitt Cancer Center awarded $3.2 million grant to study bone metastasis in prostate cancer
Moffitt researchers David Basanta, Ph.D., and Conor Lynch, Ph.D., have been awarded a U01 grant to investigate prostate cancer metastasis.
More Prostate Cancer News and Prostate Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.